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Abstract
Objective. To assess whether the proportion of primary care physicians implementing full body skin examination (FBSE) to
screen for melanoma changed over time.
Methods. Meta-regression analyses of available data. Data Sources: MEDLINE, ISI, Cochrane Central Register of
Controlled Trials.
Results. Fifteen studies surveying 10,336 physicians were included in the analyses. Overall, 15%82% of them reported to
perform FBSE to screen for melanoma. The proportion of physicians using FBSE screening tended to decrease by 1.72%
per year (P0.086). Corresponding annual changes in European, North American, and Australian settings were 0.68%
(P0.494), 2.02% (P0.044), and 2.59% (P0.010), respectively. Changes were not influenced by national guide-
lines.
Conclusions. Considering the increasing incidence of melanoma and other skin malignancies, as well as their relative
potential consequences, the FBSE implementation time-trend we retrieved should be considered a worrisome phenomenon.
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Introduction
The incidence rate of melanoma has increased
dramatically and persistently throughout the devel-
oped and industrialized world over the past 20 years,
reaching the proportion of an epidemic disease
(1,2). It is estimated that in the United States
melanoma will have been diagnosed in about
62,480 persons by the end of 2008, with approxi-
mately 8,420 related deaths (2), establishing mela-
noma as a significant public health issue.
The problem is even more disconcerting con-
sidering the limited progress in melanoma therapy
over the last decades (3).
Worldwide, overall melanoma mortality is ris-
ing, mainly in older men, while rates are decreasing
or stabilizing for younger adults (4). Mortality from
melanoma is mainly dependent on the thickness of
the lesions at diagnosis (5). Indeed, an accurate
and timely detection of melanoma is extremely
important since early-stage disease is often curable
with simple surgical excision; therefore, early de-
tection offers the opportunity to improve survival
(6). To date, more than 80% of melanomas are
diagnosed at a localized stage, when the cure rate is
high (7).
One of the most important early detection
strategies is full body skin examination (FBSE)
which is painless, rapid, and easy to perform (8,9)
and does not require technological skill (4). Full
body skin examination can also detect non-mela-
noma skin cancers (basal cell carcinoma (BCC) and
squamous cell carcinoma (SCC)), early detection of
Correspondence: Antonis Valachis, PACMeR Researcher, Lasthenous 8, PO 72200, Ierapetra, Crete, Greece. E-mail: valachis@hotmail.com
(Received 29 August 2008; accepted 12 September 2008)
Upsala Journal of Medical Sciences. 2009; 114: 3240
ISSN 0300-9734 print/ISSN 1502-4725 online # 2009 Informa UK Ltd. (Informa Healthcare, Taylor & Francis AS)
DOI: 10.1080/03009730802579620which leads to better quality of life and less financial
implication for health services (10).
Nevertheless, there is only one randomized
controlled trial evaluating the implementation of
FBSE among the general population but this was
recently disbanded due to lack of governmental
funding (11,12). Consequently, since it is unproven
(at level I or II of evidence) whether or not skin
screening would be effective in reducing mortality
from melanoma, guide-lines concerning FBSE lack
consensus or are still controversial (1316) (Table I).
Despite the conflicting evidence, the high cur-
ability of melanoma in the early stage and the non-
invasive screening procedure with full body skin
examination argue for the potential utility of mela-
noma screening. In this context, since large numbers
of the population visit physicians at regular intervals
(17), primary care physicians may play an essential
role in screening procedures for skin malignancies.
Indeed, melanoma patients typically have contact
with their physicians in the year before diagnosis
(18). Thus, the assistance of primary care physicians
may hopefully result in the enhancement of early
diagnosis rate.
These considerations led us perform a systema-
tic review of the medical literature in order to
evaluate the overall FBSE screening practice among
primary care physicians and its trend over time.
Taking into account that screening implementation
might be influenced by the geographic areas
analyzed (Australia versus Europe versus North
America), and by national guide-line recommenda-
tions, separate meta-regression analyses were per-
formed.
Methods
Identification of eligible studies
We searched MEDLINE, ISI Web of Science, and
the Cochrane Central Register of Controlled Trials
(last search, January 2008) using combinations of
terms such as screening, prevention, melanoma, skin
cancer, primary care, prescription,a n dpractice. We set
no language or geographical restriction. We also
searched the PACMeR (Panhellenic Association for
Continual Medical Research) archives for relevant
articles and perused the references of the potentially
eligible articles to identify reports that may have
been missed by the electronic searches.
Eligibility criteria
We considered eligible all cross-sectional surveys or
controlled trials providing information on the pro-
portion of primary care physicians who reported
performing skin examination for screening purposes,
with either general population or among high-risk
population subgroups. We evaluated all relevant
studies, regardless of whether or not the correspond-
ing proportion was a primary outcome. We excluded
allqualitativeresearch reportsbecause their sampling
methods and stopping rules do not ensure a repre-
sentative sample and because the thematic coding of
the main findings is formulated post hoc by the
researchers. Physicians with specialties that are
usually encountered in non-primary care settings
were excluded from the calculations unless it was
clearly stated that they were indeed primary care-
oriented. We did not consider information pertaining
to beliefs or personal views of physicians regarding
the role offull body skinexamination,asthese maybe
different from actual practice.
Definitions and outcomes
We considered persons at high risk who were
characterized as such in the primary report (e.g.
family history, presence of many/atypical moles, fair
skin). Screening by continent referred to prevalence
of skin cancer screening by physicians in three
different regions: Australia/New Zealand, Europe,
and North America. Screening by guide-lines re-
ferred to prevalence of skin cancer screening by
physicians regarding the presence of guide-lines for
skin cancer when each study was conducted. Three
Table I. Skin cancer screening recommendations from various organizations.
Organization Recommendation
American Cancer Society (13)
Age ] 20: annual complete skin examination as part of cancer-related
check-up
Canadian Task Force on the
Periodic Health Examination (14)
There is poor evidence to include or exclude from the periodic health
examination of the general population; there is fair evidence for the inclusion
of total body skin examination for a very select subgroup of individuals
US Preventive Services Task Force (15)
The evidence is insufficient to recommend for or against routine screening
for skin cancer using a total body skin examination for the early detection of
cutaneous melanoma, basal cell cancer, or squamous cell skin cancer
American Academy of Dermatology (16) Annual complete skin examination for all patients
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national authorities suggest to implement melanoma
screening practice among the overall population; 2)
national authorities do not advocate implementation
of screening practice for melanoma; 3) not assessa-
ble (NA) in case national guide-lines were absent or
in case national guide-lines from different authorities
were conflicting.
We aim to evaluate 1) the proportion of primary
care physicians who declare to perform full body
skin examination to screen for skin malignancy and
its changes over time; 2) the regional distribution of
the phenomenon (Australia versus Europe versus
North America); and 3) the relative impact of the
presence of national guide-lines.
Data extraction
We extracted information from each eligible study.
The data recorded included the first author’s name,
journal and year of publication, place and country of
origin, study design, physician inclusion and exclu-
sion criteria, number of enrolled and analyzed
physicians, number of physicians who reported
performed or who actually performed full body
skin examination for screening, method used to
measure study outcomes (standard or telephone
interview, questionnaire, patient medical record re-
view or the use of actors paying unannounced visits
to the physician), population screened (general
population or high-risk subgroup), and definition
of high-risk population (if applicable).
In controlled studies that compared the perform-
ing rates between a group of physicians who received
educational interventions and a control group not
exposed to the educational program, only physicians
in the control group were considered eligible.
Similarly, in interventional studies in which screen-
ing attitudes were evaluated before and after an
educational intervention, we considered only base-
line data (before the educational intervention).
Analyses
The study was the unit of analyses. For each of the
aforementioned outcomes, we calculated whether
the proportion of physicians who perform full body
skin examination for skin cancer screening changed
over time, using random effects meta-regression
analyses (19). Meta-regressions are variance-
weighted least-square regressions, in which the
within-study and between-study variability of the
pertinent proportions are accounted for. Summary
proportions were estimated using the general inverse
variance random effects model (20), which allows
for between-study heterogeneity (dissimilarity) and
incorporates it into the calculations (21). Hetero-
geneity in each subgroup was assessed using Fisher’s
exact test.
Unless otherwise specified, all P-values are
2-tailed, and PB0.05 indicates formal statistical
significance.
Results
Eligible studies
The electronic searches yielded 372 items: 240 from
MEDLINE, 125 from ISI Thompson, and 7 from
Cochrane Central. Of those, 51 reports were scru-
tinized in full text. We identified 17 potentially
eligible articles. Among those, 14 reports published
between 1987 and 2004 were considered eligible
(2235) and pertain to 15 potentially eligible studies.
Three reports were considered not eligible since
pertaining to beliefs or personal views rather than
practices (3638) (Figure 1). Characteristics of
eligible studies are reported in Table II.
Overall, 6,816 primary care physicians entered
analyses. Sample sizes in the studies ranged from 46
to 1694 analyzed primary care physicians. In all
studies, the information about performing FBSE
was self-reported.
Three studies were from New Zealand and
Australia (23,25,28), three from Europe (France)
(27,32,33), and nine from North America (USA).
All European studies were from France, while all
North American trials were from the USA. Most
studies did not include the exact phrasing of the
questions used to ask physicians about their skin
cancer screening awareness. Similarly, most studies
did not evaluate physicians’ beliefs so we could not
analyze discrepancies in physician beliefs and atti-
tudes.
Analyses
Overall. 15% to 82% of primary care physicians
reported to perform full body skin examination for
skin cancer screening purpose. The lowest rate was
recorded in a US study (24) when there were guide-
lines against skin cancer screening strategies. The
highest FBSE rate was recorded in an American
study (22) when there were national guide-lines
suggesting skin cancer screening in general popula-
tion. When all studies were considered, the propor-
tion of physicians who performed FBSE seemed to
decrease by 1.72% per year, but this was not
statistically significant (P0.086; 15 studies with
6,816 analyzed physicians) (Figure 2A).
34 A. Valachis et al.Regional distribution. There is a decreasing trend by
0.68% per year (P0.494; 3 studies with 1,017
analyzed physicians) in the proportion of French
physicians who perform FBSE. The trend became
statistically significant when only studies from the
USA (n9 studies) were analyzed (annual decrease
2.02%; P0.044). The decreasing trend was re-
versed when the analysis was related to studies from
New Zealand or Australia (n3 studies). We
estimated a 2.59% annual increase at FBSE rates
in these three studies (P0.010; 1,112 analyzed
physicians) (Figure 2B). The proportion of primary
care physicians who performed FBSE was more than
50% in all Australian reports.
Presence of guide-lines. The presence of national
guide-lines was not found to have any statistical
significant impact on skin examination performance.
We estimated a border-line decreasing tendency of
0.07% per year in the percentage of physicians who
perform FBSE (P0.947; 1,393 analyzed physi-
cians) in three studies which were conducted when
national guide-lines did not advocate implementa-
tion of melanoma screening. This tendency became
stronger (annual decrease 0.94%; P0.348) in eight
studies with absent or conflicting guide-lines and
even stronger, but not statistically significant (annual
decrease 1.72%; P0.085), in four studies with
guide-lines which suggest skin cancer screening
practices in general population (Figure 2C).
Population at risk. Only three studies (26,29,35)
analyzed the percentage of primary care physicians
who performed full body skin examination in high-
risk populations. Consequently, due to the paucity of
available data, meta-regression analyses were not
performed for this outcome. All studies were from
the USA and were reporting the proportion of
physicians performing FBSE in both general popu-
lation and high-risk individuals. Overall, we note
that the proportion of physicians who report to
implement FBSE was increased in the high-risk
setting (from 31%, 15%, and 32% in the general
population to 52%, 45%, and 59% in high-risk
individuals respectively).
Discussion
Full body skin examination by primary care physi-
cians may be an effective tool in reducing ad-
vanced-stage and even mortality rates of melanoma.
According to the only population-based rando-
mized controlled trial, the specificity of FBSE for
melanoma detection is comparable to that of other
established population screening procedures for
cancer, including mammography (12). Further-
more, FBSE is able to detect not only melanoma
but also many non-melanoma malignant skin le-
sions (12), and the early detection of these malig-
nancies might result in better quality of life for
372 potentially relevant reports identified
and screened for retrieval from electronic
search:
240 PubMed
125 ISI Thompson Library
7 Cochrane Library
51 potentially eligible reports retrieved
40 reports excluded upon full text
search
3 reports retrieved from cross-
searching of references
14 eligible reports pertaining to 15 eligible
studies
321 reports excluded on basis of
title or abstract
Figure 1. Flow chart of the study selection.
Time-trend of melanoma screening practice 35Table II. Characteristics of eligible studies.
Source, publication year Enrollment, country No. analyzed/characteristics of enrolled physicians Method Guide-lines Setting
Resnicow (22), 1987 NA/USA 146 and 129/Randomly selected Society of Teachers of Family
Medicine and American Academy of Family Physicians-listed
family physicians
Mailed questionnaire Yes General population
Harper (23), 1991 1990/New Zealand 210/General physicians in the Canterbury Area Health
Board-listed held by the area health board
Mailed questionnaire Yes General population
Costanza (24), 1993 1990/USA 488/Primary care physicians in Massachusetts randomly
selected from a list provided by the Folio company
Mailed questionnaire No General population
Lowe (25), 1994 1991/Australia 46/All GPs from three regional towns in Queensland:
Bundaberg, Cairns, Mount Isa
Interview with questionnaire Yes General population
Dolan (26), 1995 1994/USA 50/Resident physicians in an academic general internal medicine
practice
Mailed questionnaire No General and high-risk
population
Garcia (27), 1996 NA/France 163/GPs working in Picardy, selected with the assistance of
the Union Regionale des Medecins de Picardie
Telephone interview/mailed
questionnaire
NA General population
Sladden (28), 1999 1996/Australia 855/Nationwide random sample of family physicians Mailed questionnaire No General population
Kirsner (29), 1999 NA/USA 191/Random sample of primary care providers,
membership enrollment from Dade County, Florida
and New Haven, Connecticut
Mailed questionnaire NA General and high-risk
population
Saraiya (30), 2000 19931994/USA 1694/Randomly selected US women physicians from American
Medical Association’s database
Mailed questionnaire NA General population
Altman (31), 2000 1999/USA 1363/Random sample primary care physicians from the Official
American Board of Medical Specialists directory of Board-certified
medical specialists
Mailed questionnaire NA General population
Denise (32), 2003 2002/France 374/General physicians listed in Ordre des Medecines du
Haut-Rhin
Mailed questionnaire NA General population
Ganry (33), 2004 2003/France 480/General practitioners working in Picardy
Mailed questionnaire NA General population
Friedman (34), 2004 NA/USA 247/Random sample from the membership files of the
Connecticut state Medical Society
Mailed questionnaire NA General population
Geller (35), 2004 2002/USA 380/Randomly selected physicians from American
Medical Association’s medical marketing services’
database
Mailed questionnaire NA General and high-risk
population
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Figure 2. Proportion of primary care physicians who declare to perform full body skin examination over time. A: Overall (all eligible studies
included). B: Analysis by continent. C: Analyses by presence of guide-lines. (A-NZAustraliaNew Zealand; Yesnational authorities
suggest to implement melanoma screening practice among the overall population; NOnational authorities do not advocate
implementation of screening practice for melanoma; NAnot assessable (national guide-lines absent or conﬂicting)).
Time-trend of melanoma screening practice 37patients, anticipating major disfigurement, reducing
the need for expensive reconstructive surgery, and
(to a lesser extent) preventing mortality.
Nonetheless, in the primary care setting the
frequency of skin cancer examination rates are low
in various reports (26,29,35) and remarkably lower
than screening for breast, cervical, and colorectal
cancers (31,33,39).
We observed a wide range in the proportion of
primary care physicians who perform FBSE for skin
cancer screening purposes among eligible studies.
Time seemed to reduce the proportion of primary
care physicians who perform FBSE. This trend was
found to have different geographical patterns, while
it is not influenced by the presence/absence of
national guide-lines.
Young et al. showed that more than 40% of
general practitioners reported that they were not
aware of skin cancer screening guide-lines (40).
Consequently, the establishment of national guide-
lines might not be enough to improve cancer screen-
ing participation.
In any case, considering the rising incidence of
melanoma, the reduction in melanoma screening
procedures is a particularly worrying phenomenon.
We can hypothesize that lack of data supporting the
value of skin cancer screening, in contribution to
adverse effects of screening procedures, might po-
tentially lead to this slow drop. Additionally, while
there are no serious risks from FBSE, the examina-
tion may be embarrassing to some patients (41).
Moreover, a misdiagnosis of melanoma has a serious
emotional and financial effect on the patient (42)
since it could result in unnecessary treatment.
Screening also detects large numbers of benign
skin conditions which are very common in the
elderly and could lead to additional biopsies and
unnecessary or expensive procedures. Thereafter,
considering that the Queensland screening trials
were disbanded because of lack of governmental
funding, there is actually no study able to estimate
the balance of potential benefit of screening of skin
malignancies. Consequently, in view of the hypothe-
tical screening benefits from indirect evidence (e.g.
reduction of mortality), the implementation of
randomized controlled trials aiming to evidence
real pros and cons of FBSE is essential.
In contrast to French and US practices, in New
Zealand and Australia the proportion of primary
care physicians who declare to perform full body
skin examination for screening purposes is rising.
The higher incidence of melanoma in these two
regions, compared with the USA and southern
European countries (4,43), and the presence of
health promotion activities over the past 20 years
(44) may be possible explanations for the increasing
interest and awareness of skin screening activities
(45). Melanoma screening and early detection is
considered the most likely cause of the recent
statistically significant decreases in mortality ob-
served in Australia (46). The intention to screen is
one of the best and most consistent predictors of
screening attendance and reattendance (47) and has
been shown to be strongly associated with actual
screening behavior for breast and colorectal cancer
(48,49). Consequently, it is of high importance to
organize educational programs for physicians as well
as for the general population about skin cancer
screening procedures in order to achieve high
participation in melanoma screening.
There are some limitations of this study. Firstly,
there were only 15 eligible studies. Only three
reports were from Australia/New Zealand and
three from France. Moreover, there were only three
studies with presence of guide-lines respectively
against and four studies in favor of skin cancer
screening. Therefore, these findings may not be
generalized. Secondly, data were derived from
cross-sectional studies, which have a limited internal
validity and are sensitive to several biases. These
surveys have commonly low response rates (50).
Furthermore, the vast majority of eligible studies
used mailed questionnaires, a method in which
incomplete or missing response is likely to be more
frequent (51). Overall, 6,816 (65.9%) of 10,336
eligible physicians were analyzed in the eligible
studies. This raises further concerns about the
generalizability of the results, because non-respon-
ders may have systematically different characteristics
from those of responders. Finally, the exact question
that was used to assess the outcome of interest was
not clearly described in most studies. Unfortunately,
the effect of different phrasing on our findings
cannot be assessed.
Allowing for these caveats, and admitting that
such biases may in part affect our study outcomes,
the overall results from our comprehensive review
are considered to be valid.
Conclusion
Despite the rising incidence and persistent mortality
of melanoma, skin cancer screening rates are shrink-
ing over time. Considering the potential usefulness
of skin cancer screening, future efforts should aim
firstly to estimate balanced benefits for FBSE
screening, and secondly to implement relative evi-
dence-based educational and screening programs.
Considering the incidence of melanoma and other
skin malignancies, and taking into account the
38 A. Valachis et al.relative potential consequences, the FBSE imple-
mentation time-trend we retrieved should be con-
sidered a worrying phenomenon.
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